Receives Milestone Payment from Kyocera
- Regeneus receives payment of 100M JPY (~A$1.3M) from Kyocera Corporation
- Payment follows the completion of execution of the agreement between the two companies for Kyocera to exclusively develop and commercialise Regeneus' lead stem cell platform technology Progenza for the treatment of Knee Osteoarthritis in Japan
Pursuant with the terms of the agreement, Regeneus is expected to receive a further US$4M from Kyocera in October 2020. The Company will notify the market once this payment has been received.
About Regeneus Ltd
Regeneus Ltd (ASX:RGS) is a Sydney-based clinical-stage regenerative medicine company using stem cell technologies to develop a portfolio of novel cell-based therapies to address significant unmet medical needs in the human health markets with a focus on osteoarthritis and other musculoskeletal disorders, neuropathic pain and dermatology.